{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:15:47Z","timestamp":1781075747674,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL144406"],"award-info":[{"award-number":["R01HL144406"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high-TB-burden countries. Despite established safety and tolerability in efficacy trials, 3HP-related adverse events (AEs) could differ in routine settings. Real-world data on AE type, frequency, and timing are crucial for health systems considering 3HP programmatic scale-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed AEs among people with human immunodeficiency virus (HIV) participating in a pragmatic implementation trial of facilitated 3HP taken by directly observed therapy (DOT) or self-administered therapy (SAT) in Kampala, Uganda, and classified them using the Common Terminology Criteria for Adverse Events. We assessed AE timing and summarized related clinical actions including laboratory tests, diagnoses made, medications prescribed, and treatment interruptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1655 people with HIV treated between July 2020 and September 2022, 270 (16.3%) reported 451 events; main issues included general (7%), nervous system (6%), musculoskeletal (5%), gastrointestinal (5%), and dermatologic (3%) disorders. Most (61%) occurred within 6 weeks of initiating 3HP. Among those with events, 211 (78%) required further clinician evaluation, 202 (75%) required laboratory testing, 102 (38%) had medications prescribed, 40 (15%) had treatment paused, and 14 (5%) discontinued 3HP. Women, those multidimensionally impoverished, and DOT recipients were more likely to report an AE. SAT users and later enrollees were more likely to have 3HP interrupted or stopped due to an AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a routine setting, 3HP was safe, with 16% of people with HIV reporting AEs and only 3% requiring temporary or permanent treatment interruption. These findings support 3HP expansion in routine HIV\/AIDS care settings for TB prevention.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT03934931.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae667","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T07:22:23Z","timestamp":1731482543000},"source":"Crossref","is-referenced-by-count":4,"title":["Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-8681","authenticated-orcid":false,"given":"Jillian L","family":"Kadota","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-6433","authenticated-orcid":false,"given":"Allan","family":"Musinguzi","sequence":"additional","affiliation":[{"name":"Department of Research, Infectious Diseases Research Collaboration , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1234-4321","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne E","family":"Aschmann","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4013-9692","authenticated-orcid":false,"given":"Lydia","family":"Akello","sequence":"additional","affiliation":[{"name":"Department of Research, Infectious Diseases Research Collaboration , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Welishe","sequence":"additional","affiliation":[{"name":"Department of Research, Infectious Diseases Research Collaboration , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2701-2330","authenticated-orcid":false,"given":"Jane","family":"Nakimuli","sequence":"additional","affiliation":[{"name":"Department of Research, Infectious Diseases Research Collaboration , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-7544","authenticated-orcid":false,"given":"Christopher A","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-9290","authenticated-orcid":false,"given":"Noah","family":"Kiwanuka","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P J","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-4183","authenticated-orcid":false,"given":"Achilles","family":"Katamba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Epidemiology and Biostatistics Unit, Makerere University College of Health Sciences , Kampala ,","place":["Uganda"]},{"name":"Uganda Tuberculosis Implementation Research Consortium, Walimu , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-7475","authenticated-orcid":false,"given":"David W","family":"Dowdy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-2601","authenticated-orcid":false,"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Division of Pulmonary Diseases and Critical Care Medicine, University of California, Irvine , Orange, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-7640","authenticated-orcid":false,"given":"Fred C","family":"Semitala","sequence":"additional","affiliation":[{"name":"Department of Research, Infectious Diseases Research Collaboration , Kampala ,","place":["Uganda"]},{"name":"Department of Medicine, Makerere University College of Health Sciences , Kampala ,","place":["Uganda"]},{"name":"Department of Research, Makerere University Joint AIDS Program , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2024112308505980900_ofae667-B1","volume-title":"The End TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015","author":"World Health Organization","year":"2014"},{"key":"2024112308505980900_ofae667-B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S2213-2600(23)00409-5","article-title":"The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis","volume":"12","author":"Millington","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2024112308505980900_ofae667-B3","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024112308505980900_ofae667-B4","author":"Farenc","year":"2014"},{"key":"2024112308505980900_ofae667-B5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024112308505980900_ofae667-B6","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2024112308505980900_ofae667-B7","doi-asserted-by":"crossref","first-page":"e1004356","DOI":"10.1371\/journal.pmed.1004356","article-title":"Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: a single-center randomized trial","volume":"21","author":"Semitala","year":"2024","journal-title":"PLoS Med"},{"key":"2024112308505980900_ofae667-B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13012-020-01025-8","article-title":"Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda","volume":"15","author":"Kadota","year":"2020","journal-title":"Implement Sci"},{"key":"2024112308505980900_ofae667-B9","author":"US Department of Health and Human Services","year":"2017"},{"key":"2024112308505980900_ofae667-B10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024112308505980900_ofae667-B11","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/cid\/ciad083","article-title":"Symptoms and systemic drug reactions in persons receiving weekly rifapentine plus isoniazid (3HP) treatment for latent tuberculosis infection","volume":"76","author":"Sadowski","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024112308505980900_ofae667-B12","author":"United Nations Development Program","year":"2023"},{"key":"2024112308505980900_ofae667-B13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.7326\/M20-7577","article-title":"Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial","volume":"174","author":"Churchyard","year":"2021","journal-title":"Ann Intern Med"},{"key":"2024112308505980900_ofae667-B14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/tropicalmed9010004","article-title":"Uptake and completion of tuberculosis preventive treatment using 12-dose, weekly isoniazid-rifapentine regimen in Bangladesh: a community-based implementation study","volume":"9","author":"Rahman","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2024112308505980900_ofae667-B15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"2024112308505980900_ofae667-B16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024112308505980900_ofae667-B17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1060028019888855","article-title":"Evaluation of 3 months of once-weekly rifapentine and isoniazid for latent tuberculosis infection","volume":"54","author":"Walker","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2024112308505980900_ofae667-B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5588\/pha.22.0030","article-title":"Reasons for poor uptake of TB preventive therapy in South Africa","volume":"12","author":"Baloyi","year":"2022","journal-title":"Public Health Action"},{"key":"2024112308505980900_ofae667-B19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1186\/s12889-021-12056-1","article-title":"Impact of socio-economic factors on tuberculosis treatment outcomes in north-eastern Uganda: a mixed methods study","volume":"21","author":"Nidoi","year":"2021","journal-title":"BMC Public Health"},{"issue":"Suppl 6","key":"2024112308505980900_ofae667-B20","doi-asserted-by":"crossref","first-page":"s79","DOI":"10.7861\/clinmedicine.16-6-s79","article-title":"Beyond pills and tests: addressing the social determinants of tuberculosis","volume":"16","author":"Wingfield","year":"2016","journal-title":"Clin Med (Lond)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae667\/60678486\/ofae667.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae667\/60793729\/ofae667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae667\/60793729\/ofae667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:51:13Z","timestamp":1732333873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae667\/7900646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae667","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.08.24311632","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"ofae667"}}